← Leaderboards
Kun Qing
University Of Virginia
$2,843,545
Attributed
$5,703,720
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $786.6K · FY2015–25$1M$750K$500K$250K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,703,720 · 3
By mechanism
R01$5,269,220 · 2
R21$434,500 · 1
Top collaborators
- Yun Michael Shim5 shared
- Jia Guo2 shared
- Yun Jiang2 shared
Most similar at University Of Virginia
Same institution · by research overlap
- Yun Michael Shim$6,424,060
- William Gerald Teague$5,830,751
- Harish Narasimhan$85,695
- Imre Noth$12,167,659
Others in their field
Top investigators on “Image”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$332,241,999
- Leonard Freedman · Leidos Biomedical Research, Inc.$321,574,964
- Charles Mattias Mountain · Association Of Universities For Research In Astronomy, Inc.$217,904,052
- Ethan Schreier · Associated Universities, Inc.$206,468,864
Research focus
ImageResolutionBloodMapsMagnetic Resonance ImagingImaging TechniquesSensitivity And SpecificityFutureTissuesLungChronic Obstructive Airway DiseaseAnatomyClinical AssessmentsInflammationGasesHigh Resolution Computed TomographyAlveolarBaseFda ApprovedCause Of DeathDiagnosisCharacteristicsBronchodilator AgentsAffect
Grant awards (9)
Quantitative MRI to automatically delineate intraprostatic tumor for radiation therapy$648,830
R01 · FY2025 · CA · contact PI
Quantitative MRI to automatically delineate intraprostatic tumor for radiation therapy$704,563
R01 · FY2024 · CA · contact PI
Hyperpolarized Xenon-129 MRI: a new multi-dimensional biomarker to determine pulmonary physiologic responses to COPD therapeutics$786,595
R01 · FY2021 · HL
Hyperpolarized Xenon-129 MRI: a new multi-dimensional biomarker to determine pulmonary physiologic responses to COPD therapeutics$786,595
R01 · FY2020 · HL
Hyperpolarized Xenon-129 MRI: a new multi-dimensional biomarker to determine pulmonary physiologic responses to COPD therapeutics$786,595
R01 · FY2019 · HL
Hyperpolarized Xenon-129 MRI: a new multi-dimensional biomarker to determine pulmonary physiologic responses to COPD therapeutics$780,775
R01 · FY2018 · HL
Hyperpolarized Xenon-129 MRI: a new multi-dimensional biomarker to determine pulmonary physiologic responses to COPD therapeutics$775,267
R01 · FY2017 · HL
Xe129 MRI of the Lung: A New Technology to Assess Treatment for COPD$197,500
R21 · FY2016 · HL · contact PI
Xe129 MRI of the Lung: A New Technology to Assess Treatment for COPD$237,000
R21 · FY2015 · HL · contact PI